BioStem Technologies, Inc. (BSEM)

Century Therapeutics (NASDAQ:IPSC) and BioStem Technologies (OTCMKTS:BSEM) Financial Analysis

BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio

BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio

BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform

BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility

BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility

BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier

BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier

BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference

BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal

Comparing BioStem Technologies (OTCMKTS:BSEM) and Enlivex Therapeutics (NASDAQ:ENLV)

BioStem Technologies to Present at the Sidoti MicroCap Conference

BioStem Technologies Q2 Earnings Call Highlights

BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call Transcript

BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates

BioStem Technologies Reports Second Quarter 2026 Financial Results

BioStem Technologies Reports Second Quarter 2026 Financial Results

BioStem Technologies Announces Nasdaq Uplisting